Cerebrolysin Research Overview

Cerebrolysin is a biological drug product consisting of approximately 80% low-molecular-weight neuropeptides and 20% free amino acids derived from standardized enzymatic hydrolysis of porcine brain proteins. It has been in clinical use for more than five decades in parts of Europe and Asia, where it is administered intravenously or intramuscularly for acute ischemic stroke and Alzheimer's disease. It is not approved by the FDA and has not gained regulatory acceptance in most Western markets. Independent systematic reviews, including multiple Cochrane analyses, have consistently found the evidence base weak, heterogeneous, or insufficient to support its routine clinical use.

What Is Cerebrolysin?

Cerebrolysin is manufactured by EVER Neuro Pharma (formerly Ebewe Pharma) in Austria. The porcine brain proteins are enzymatically digested under controlled conditions to produce a defined molecular weight fraction: the active product contains peptide fragments typically below 10,000 Da alongside free amino acids. The precise peptide composition is not fully characterized at the molecular level, which presents challenges for regulatory review by agencies that require well-defined chemical entities.

The product is registered and marketed in Russia, Ukraine, China, South Korea, and numerous other countries in Eastern Europe and Asia. In Austria and several EU member states, it has been available under national authorizations. It is typically provided as a concentrated solution for parenteral injection. Research-compound vendors in Western markets supply it for laboratory use.

Mechanism of Action

Because Cerebrolysin is a heterogeneous mixture, its mechanism cannot be attributed to a single molecular target. Proposed mechanisms from preclinical work include neurotrophic factor-like activity — some peptide fractions appear to mimic the effects of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and other neurotrophins. Studies have also reported reduced amyloid precursor protein processing, decreased tau hyperphosphorylation in animal models, anti-apoptotic signaling, and anti-excitotoxic effects.

The problem with this mechanistic picture is that it is largely preclinical and cannot be directly linked to the heterogeneous clinical outcomes in human trials. The composition variability across manufacturing batches and the incomplete characterization of which specific peptide fractions drive which effects make mechanism-to-outcome translation difficult.

What the Research Shows

Stroke: The Cochrane review by Ziganshina and colleagues on Cerebrolysin for acute ischemic stroke was last updated in 2023. It analyzed seven randomized controlled trials enrolling 1,773 participants. The reviewers concluded that moderate-certainty evidence indicates Cerebrolysin probably has no beneficial effect on preventing all-cause death or serious adverse events in acute ischemic stroke. The 2023 update explicitly stated that the reviewers considered it would be unethical to conduct further trials given the absence of demonstrated benefit.

The CASTA (Cerebrolysin Acute Stroke Treatment in Asia) trial, a Phase 3 multicenter RCT enrolling over 1,000 patients in Asia, found only a trend toward improved outcomes that did not reach statistical significance on its primary endpoint. It provided the largest single data set but did not establish efficacy.

Alzheimer's disease: A 2015 meta-analysis of randomized controlled trials (Allegri et al., PMID 25832905) found that Cerebrolysin was statistically superior to placebo on cognitive function measures at 4 weeks. However, methodological limitations including high risk of bias, small sample sizes, and short follow-up durations were noted. A Cochrane review on Cerebrolysin for Alzheimer's (CD003801) has noted inadequate evidence for routine clinical use.

Vascular dementia: A separate Cochrane review on Cerebrolysin for vascular dementia (CD008900) found that courses of intravenous Cerebrolysin improved cognition and general function relative to placebo, but noted that the analyses were limited by heterogeneity and high risk of bias in included papers. The reviewers concluded the data are not definitive.

The overall picture is: a product with decades of clinical use in non-Western markets, a mixture of positive signals in small or methodologically weak trials, and consistent failure to demonstrate convincing efficacy in the larger or more rigorously designed studies. Researchers approaching this compound should read the primary Cochrane literature, not vendor summaries.

Pharmacokinetics

Cerebrolysin is administered by intravenous infusion or intramuscular injection. As a mixture of small peptides, systemic distribution is expected, and preclinical data suggest that some fractions cross the blood-brain barrier, which is plausible given the low molecular weights involved. Formal PK characterization of individual constituent peptides in humans is not available in the published literature, which is a significant limitation for mechanistic interpretation of clinical results. The preparation is not orally bioavailable.

Reported Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

In stroke trials, Cerebrolysin has typically been evaluated at intravenous doses of 10–30 mL daily for 10–21 days. In Alzheimer's and vascular dementia trials, doses of 5–30 mL administered intravenously over multiple weeks have been used. These dose figures reflect trial protocols conducted in supervised clinical settings. The product is a concentrated solution; volume dosing corresponds to specific neuropeptide mass amounts that vary by product concentration.

Storage and Handling

Cerebrolysin is supplied as a solution for injection, not a lyophilized powder. Unopened vials should be stored at 15–25 °C and protected from freezing and direct light. Once a vial is opened, the solution should be used immediately and not stored. The product contains no preservatives; sterile technique is required for preparation of infusions. As a biological product, it should not be used if the solution shows discoloration or particulate matter.

What Cerebrolysin Is NOT

Cerebrolysin is not an FDA-approved drug. It is not a defined single-entity peptide or small molecule; it is a biological mixture and cannot be considered equivalent to a synthetic research peptide with a known sequence. It is not a proven treatment for stroke or Alzheimer's disease by Western regulatory standards. The Cochrane evidence for its use in acute ischemic stroke is negative at moderate certainty. Vendors and proponents who describe Cerebrolysin as an established neuroprotective or cognitive-enhancing agent are citing a literature base that independent reviewers have consistently characterized as inadequate, biased, or negative.

References

1. Ziganshina LE et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10:CD007026. PMID 37818733.

2. Cochrane: Cerebrolysin for vascular dementia. CD008900.

3. Allegri RF et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. J Alzheimers Dis. 2015;47(3):781–791. PMID 25832905.

4. ClinicalTrials.gov: CASTA – Safety and Efficacy of Cerebrolysin in Patients with Acute Ischemic Stroke. NCT00868283.